Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3519

1.

[The Technical Evaluation of HCV Screening Assay].

Kobayashi Y, Tomoda M, Miura H, Satho A.

Rinsho Byori. 2017 Feb;65(2):147-152. English, Japanese.

PMID:
30762980
2.

Impact of Apo E gene polymorphism on HCV therapy related outcome in a cohort of HCV Egyptian patients.

Gomaa HE, Mahmoud M, Saad NE, Saad-Hussein A, Ismail S, Thabet EH, Farouk H, Kandil D, Heiba A, Hafez W.

J Genet Eng Biotechnol. 2018 Jun;16(1):47-51. doi: 10.1016/j.jgeb.2017.10.008. Epub 2017 Oct 12. Review.

3.

Significance of growth differentiation factor 15 in chronic HCV patients.

Halim MH, Abdulla NA, Kamel A, El Maksoud NA, Ragab HM.

J Genet Eng Biotechnol. 2017 Dec;15(2):403-407. doi: 10.1016/j.jgeb.2017.08.004. Epub 2017 Aug 12.

4.

Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection.

Otsuka T, Kawaguchi Y, Mizuta T, Ide Y, Koga F, Kumagai T, Yoshioka W, Murayama K, Rikitake O, Ikeda Y, Ozaki I.

JGH Open. 2017 Nov 28;1(4):148-152. doi: 10.1002/jgh3.12026. eCollection 2017 Dec.

5.

Association of interferon gamma gene polymorphism and susceptibility to hepatitis C virus infection in Egyptian patients: A multicenter, family-based study.

El-Bendary M, Neamatallah M, Elalfy H, Besheer T, El-Setouhy M, Kasim N, Abou El-Khier NT, Kamel E, Eladl AH, El-Waseef A, Abdel-Aziz AF, Esmat G.

JGH Open. 2017 Dec 19;1(4):140-147. doi: 10.1002/jgh3.12024. eCollection 2017 Dec.

6.

HOW TO TEST FOR CURRENT OR PAST HCV INFECTION (HCV EXPOSURE) – choice of serological assay and testing strategy.

WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization; 2017 Feb. No abstract available. 8.

7.

ASSESSMENT OF HCV TREATMENT RESPONSE - test of cure.

WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization; 2017 Feb. No abstract available. 12.

8.

DETECTION OF VIRAEMIC HCV INFECTION – to guide who to treat.

WHO Guidelines on Hepatitis B and C Testing. Geneva: World Health Organization; 2017 Feb. No abstract available. 11.

9.

Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India.

Garg G, Dixit VK, Shukla SK, Singh SK, Sachan S, Tiwari A, Yadav VK, Yadav DP.

J Clin Exp Hepatol. 2018 Sep;8(3):241-249. doi: 10.1016/j.jceh.2017.11.011. Epub 2017 Dec 6.

PMID:
30302040
10.

A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.

Mehta G, Rousell S, Burgess G, Morris M, Wright G, McPherson S, Frenette C, Cave M, Hagerty DT, Spada A, Jalan R.

J Clin Exp Hepatol. 2018 Sep;8(3):224-234. doi: 10.1016/j.jceh.2017.11.006. Epub 2017 Nov 22.

11.
12.

Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma.

Amr KS, Elmawgoud Atia HA, Elazeem Elbnhawy RA, Ezzat WM.

Genes Dis. 2017 Dec 6;4(4):215-221. doi: 10.1016/j.gendis.2017.10.003. eCollection 2017 Dec.

13.

Viral Hepatitis.

Wiktor SZ.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 16.

14.

Genotype distribution of hepatitis C virus in 952 cases from 2014 to 2016 in Hunan Province, China.

Lei JH, Gong X, Xiao XQ, Chen Z, Peng F.

Arch Med Sci. 2018 Aug;14(5):1055-1060. doi: 10.5114/aoms.2017.70664. Epub 2017 Oct 12.

15.

Detection of the Incidence of HBV, HCV Infection and Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma-Treated Patients.

Ali K, Sial AA, Baig MT, Baig N, Ansari SH, Shamsi TS.

Hosp Pharm. 2018 Jun;53(3):194-197. doi: 10.1177/0018578717741394. Epub 2017 Nov 16.

PMID:
30147140
16.

Sugar modified pyrimido[4,5-b]indole nucleosides: synthesis and antiviral activity.

Konč J, Tichý M, Pohl R, Hodek J, Džubák P, Hajdúch M, Hocek M.

Medchemcomm. 2017 Aug 25;8(9):1856-1862. doi: 10.1039/c7md00319f. eCollection 2017 Sep 1.

17.

Hypericin inhibits hepatitis C virus replication via deacetylation and down-regulation of heme oxygenase-1.

Shih CM, Wu CH, Wu WJ, Hsiao YM, Ko JL.

Phytomedicine. 2018 Jul 15;46:193-198. doi: 10.1016/j.phymed.2017.08.009. Epub 2017 Aug 16.

PMID:
30097118
18.

Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.

Ruggeri M, Coretti S, Romano F, Kondili LA, Vella S, Cicchetti A.

Value Health. 2018 Jul;21(7):783-791. doi: 10.1016/j.jval.2017.10.021. Epub 2017 Dec 6.

PMID:
30005750
19.

A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DCSpecial Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)PLUS Meeting Abstract SummariesWith Expert Commentary by:Fred Poordad, MDChief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.

[No authors listed]

Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24. No abstract available.

20.

Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation.

Reddy S, Sharma RK, Mehrotra S, Prasad N, Gupta A, Kaul A, Singh Bhadauria D.

Clin Kidney J. 2018 Jun;11(3):429-433. doi: 10.1093/ckj/sfx112. Epub 2017 Oct 30.

Supplemental Content

Loading ...
Support Center